We could not find any results for:
Make sure your spelling is correct or try broadening your search.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologicsβ), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -8.62068965517 | 1.74 | 1.76 | 1.545 | 182752 | 1.62319725 | CS |
4 | -0.55 | -25.7009345794 | 2.14 | 2.15 | 1.54 | 180297 | 1.68953545 | CS |
12 | -1.55 | -49.3630573248 | 3.14 | 3.2399 | 1.54 | 153014 | 2.10353125 | CS |
26 | -2.09 | -56.7934782609 | 3.68 | 4.41 | 1.0779 | 300317 | 2.79409752 | CS |
52 | -12.9 | -89.0269151139 | 14.49 | 17.75 | 1.0779 | 235198 | 4.7149747 | CS |
156 | -28.41 | -94.7 | 30 | 55 | 1.0779 | 233776 | 4.83597518 | CS |
260 | -28.41 | -94.7 | 30 | 55 | 1.0779 | 233776 | 4.83597518 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions